TSLA
Tesla
-- 278.390 NVDA
NVIDIA
-- 121.410 AMD
Advanced Micro Devices
-- 113.850 PLTR
Palantir
-- 96.750 MLGO
MicroAlgo
-- 13.990 
New filing!
$Immutep (IMMP.US)$ Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.
IMP761 is the world’s first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.1,2,3 IMP761 is designed to restore balance to the immune system by enhancing the “brake” function of LAG-3to silence unregulated self-antigen-specific memory T cells. These T cells accumulate at disease sites and are the underlying cause of many autoimmune diseases.
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.
IMP761 is the world’s first therapeutic LAG-3 agonist antibody and as such is uniquely positioned in the treatment landscape for autoimmune diseases. The immune checkpoint LAG-3 has been identified as a promising target for agonist immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.1,2,3 IMP761 is designed to restore balance to the immune system by enhancing the “brake” function of LAG-3to silence unregulated self-antigen-specific memory T cells. These T cells accumulate at disease sites and are the underlying cause of many autoimmune diseases.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
103216711 : avr price 2.1, let's see how it goes
Trytosaveabit OP 103216711 : Indeed! GL